Shorted
Neuren Pharmaceuticals logo
NEU
Pharmaceuticals, Biotechnology & Life Sciences

Neuren Pharmaceuticals

Short interest
2.92%
−0.09 pp 30d
as of 8 Oct 2026
Reported shorts
3.7M
Shares on issue
126.774M

Neuren Pharmaceuticals (NEU) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Positive
5d ago

What Does Neuren (ASX:NEU) Gain From Europe's Rett Approval?

Highlights Europe has approved the first treatment for Rett syndrome in the region A US patent notice could stretch protection out to the next decade Royalties and milestones fund the company while its second drug advances Neuren Pharmaceuticals (ASX:NEU), the Melbourne-based developer of treatments for rare neurological disorders, is drawing fresh attention after its partner won European approval for Rett syndrome therapy Daybue and reported a favourable patent notice in the United States. T...

Continue reading
Kalkine
Positive
6 Oct

Are Neuren's First Dividends Landing This Week (ASX:NEU)?

Highlights Neuren is due to pay its first-ever interim dividend on Wednesday. The payout is funded by growing royalty income from a Rett syndrome drug. Several regulatory and trial milestones are approaching over coming weeks. Neuren Pharmaceuticals (ASX:NEU) is set to pay its first-ever dividend on Wednesday, a fully franked interim payout declared in August that marks a rare moment for an Australian drug developer: returning cash to owners of the stock from royalty income. The dividend deta...

Continue reading
Kalkine
Neutral
28 Sept

What lies ahead for Neuren (ASX:NEU) as FDA talks draw near?

Highlights The royalty-funded biotech is about to pay its first-ever dividend from growing Rett syndrome drug income. A European launch, a Japanese trial readout and a key US regulatory meeting cluster into the final months of the year. Regulators' views on trial design for a rarer disorder could reshape the path for its second drug. Neuren Pharmaceuticals (ASX:NEU) is heading into a dense run of catalysts, with its maiden dividend due to be paid next week and a face-to-face meeting with the ...

Continue reading
Kalkine
Neutral
25 Sept

Where Does Neuren (ASX:NEU) Go Next After European Approval?

Highlights Rett syndrome treatment cleared for sale across the European Union First commercial sale in Europe would trigger a milestone payment Biotech valuations remain exposed to a global bond rout Neuren Pharmaceuticals (ASX:NEU) is turning its attention this week to converting last month's landmark European approval of its Rett syndrome treatment into first commercial sales, the trigger for a sizeable milestone payment, even as a global bond rout weighs on growth and biotech valuations ac...

Continue reading
Kalkine
Neutral
17 Sept

What Could Neuren Pharmaceuticals (ASX:NEU) Mean for Midcaps?

Highlights Neuren Pharmaceuticals Limited (ASX:NEU) develops therapies for neurological conditions. Its clinical and commercialisation progress places it among the closely watched Midcap Stocks names. Regulatory approvals and licensing arrangements remain central to its performance. Specialist pharmaceutical developers occupy a distinct niche within the local market, and Neuren Pharmaceuticals Limited (ASX:NEU) is one of the more closely followed examples. Sitting within the Midcap Stocks cat...

Continue reading
Kalkine
Neutral
7 Aug

Neuren Pharmaceuticals (ASX:NEU) in Focus on Biotech Progress

Highlights Neuren Pharmaceuticals is drawing attention today around biotechnology progress. The update gives the sector a fresh company-specific news hook. Execution and wider market conditions remain central to the next read-through. Neuren Pharmaceuticals (ASX:NEU) is in focus today as the Australian market weighs biotechnology progress, putting the companys latest operational narrative at the centre of a busy local trading session. Why the update matters now The immediate reaction matters ...

Continue reading
Kalkine
Neutral
29 June

Neuren Pharmaceuticals (ASX:NEU) Draws Attention as Drug Pipeline Strengthens

Highlights Neuren Pharmaceuticals continues advancing its rare neurological disease pipeline while attracting renewed market attention. Progress across commercial licensing and late-stage clinical development remains central to the company's long-term strategy. Investors continue monitoring regulatory milestones, clinical trials and future commercial opportunities. Neuren Pharmaceuticals continues advancing its rare disease pipeline as clinical development, li...

Continue reading
Kalkine
Neutral
28 June

ASX 200 Set for Monday Focus: Will Neuren (ASX:NEU) and Gold Stocks Lead the Market?

Highlights The Australian share market is expected to begin the week on a positive note despite mixed overseas trading. Commodity prices, broker updates and dividend adjustments are likely to influence early market activity. Gold miners, energy companies and several dividend-paying shares remain closely watched. The Australian share market is preparing for another active trading session after ending last week with modest gains. Investors will be watching globa...

Continue reading
Kalkine
Positive
24 June

NEU (ASX:NEU) DAYBUE Royalties Lift Growth as Sales Rise

Highlights NEU (ASX:NEU) reports around growth in net sales and royalty income, driven by DAYBUE traction. Commercial partner expansion continues to support Rett syndrome treatment uptake. Market attention builds around biotech earnings visibility within the [ASX 200] healthcare sector. NEU (ASX:NEU) continues to grow royalty income from DAYBUE, with rising sales reinforcing its position as a key biotech name in the ASX healthcare sector. Australian healthcare stocks continue to attract...

Continue reading
Kalkine
Neutral
22 June

Why Is ASX:NEU Waiting on Europe Daybue Decision Shock?

Highlights Neuren Pharmaceuticals (ASX:NEU) is in focus as its partner awaits a key European regulatory decision on Daybue. Strong North American uptake of the therapy continues to underpin royalty-linked revenue expectations. The outcome could reshape the commercial pathway for Rett syndrome treatment expansion. Neuren Pharmaceuticals is in focus as a European decision on Daybue approaches, with North American success underpinning its rare disease growth narrative and global expansion ...

Continue reading